/

Empresas

Ka

No verificado

Kallyope

Sobre qué escribimos

BiotecnologíaEventosFarmacéuticaMedicina - VariosSalud

8 Comunicados de prensa

Ver todos los comunicados de prensa

04/06/2026

Ciencia

Medicina - Varios

Biotecnología

Sanidad

Farmacéutica

Salud

Eventos

Ferias y Congresos

Industria

Kallyope Presents New Data on Novel TRPM8 Channel Blocker Elismetrep for the Acute Treatment for Migraine at the American Headache Society 68th Annual Scientific Meeting

Fuente

Editor

1.00

0

22/04/2026

Kallyope’s Phase 2b Study of Elismetrep, A Novel Approach for Treating Migraine, Presented at the American Academy of Neurology Annual Meeting

Fuente

Editor

1.00

0

05/03/2026

Eventos

Ciencia

Técnica

Tecnología

Medicina - Varios

Biotecnología

Farmacéutica

Salud

Kallyope to Present Phase 2b Study Results for Elismetrep for the Acute Treatment of Migraine at the 2026 American Academy of Neurology Annual Meeting

Fuente

Editor

1.00

0

07/01/2026

Biotecnología

Sanidad

Salud

Farmacéutica

Medicina - Varios

Kallyope Announces 2026 Strategic Priorities for Migraine and Metabolism Portfolio Based on Novel Neural Circuits Platform

Fuente

Editor

1.00

0

18/12/2025

Eventos

Biotecnología

Sanidad

Salud

Farmacéutica

Kallyope To Present at the 44th Annual J.P. Morgan Healthcare Conference

Fuente

Editor

1.00

0

17/12/2025

Eventos

Biotecnología

Sanidad

Salud

Farmacéutica

Kallyope To Present at the 44th Annual J.P. Morgan Healthcare Conference

Fuente

Editor

1.00

0

08/12/2025

Industria

Biotecnología

Farmacéutica

Salud

Medicina - Varios

Kallyope Announces Positive Results from Phase 2b Study of Elismetrep for the Acute Treatment of Migraine

Fuente

Editor

1.00

0

10/09/2024

Mercado laboral

Industria

Biotecnología

Salud

Farmacéutica

Medicina - Varios

Kallyope Announces License Agreement with Novo Nordisk

Fuente

Editor

1.00

0

Seguidores

0

Compatibilidad

0